NASDAQ:ANNX

Annexon Competitors

$18.48
-1.45 (-7.28 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.26
$20.41
50-Day Range
$19.27
$29.92
52-Week Range
$15.33
$38.01
Volume137,153 shs
Average Volume159,094 shs
Market Capitalization$706.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Annexon (NASDAQ:ANNX) Vs. TARO, PTCT, INSM, PCRX, RCKT, and MOR

Should you be buying ANNX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Annexon, including Taro Pharmaceutical Industries (TARO), PTC Therapeutics (PTCT), Insmed (INSM), Pacira BioSciences (PCRX), Rocket Pharmaceuticals (RCKT), and MorphoSys (MOR).

Annexon (NASDAQ:ANNX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Annexon and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annexon00503.00
Taro Pharmaceutical Industries00103.00

Annexon presently has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Taro Pharmaceutical Industries has a consensus target price of $81.00, suggesting a potential upside of 10.05%. Given Annexon's higher probable upside, research analysts plainly believe Annexon is more favorable than Taro Pharmaceutical Industries.

Valuation & Earnings

This table compares Annexon and Taro Pharmaceutical Industries' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A$-37,180,000.00N/AN/A
Taro Pharmaceutical Industries$644.77 million4.37$244.24 million$6.3511.59

Taro Pharmaceutical Industries has higher revenue and earnings than Annexon.

Profitability

This table compares Annexon and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnnexonN/A-566.22%-32.99%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Institutional & Insider Ownership

91.2% of Annexon shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Taro Pharmaceutical Industries beats Annexon on 5 of the 9 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

91.2% of Annexon shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares PTC Therapeutics and Annexon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million8.93$-251,580,000.00($3.45)-11.28
AnnexonN/AN/A$-37,180,000.00N/AN/A

Annexon has lower revenue, but higher earnings than PTC Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PTC Therapeutics and Annexon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics05602.55
Annexon00503.00

PTC Therapeutics currently has a consensus target price of $65.10, suggesting a potential upside of 67.35%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-123.19%-76.10%-24.60%
AnnexonN/A-566.22%-32.99%

Insmed (NASDAQ:INSM) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Insmed and Annexon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$136.47 million19.67$-254,340,000.00($3.01)-8.63
AnnexonN/AN/A$-37,180,000.00N/AN/A

Annexon has lower revenue, but higher earnings than Insmed.

Analyst Ratings

This is a summary of recent recommendations for Insmed and Annexon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed00703.00
Annexon00503.00

Insmed currently has a consensus target price of $53.5714, suggesting a potential upside of 106.12%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Insmed's higher probable upside, equities research analysts clearly believe Insmed is more favorable than Annexon.

Profitability

This table compares Insmed and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-145.14%-79.58%-31.14%
AnnexonN/A-566.22%-32.99%

Summary

Insmed beats Annexon on 6 of the 9 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 5.8% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pacira BioSciences and Annexon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million6.37$-11,020,000.00$0.8670.80
AnnexonN/AN/A$-37,180,000.00N/AN/A

Pacira BioSciences has higher revenue and earnings than Annexon.

Analyst Ratings

This is a summary of recent recommendations for Pacira BioSciences and Annexon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04802.67
Annexon00503.00

Pacira BioSciences currently has a consensus target price of $78.5833, suggesting a potential upside of 29.06%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
AnnexonN/A-566.22%-32.99%

Summary

Pacira BioSciences beats Annexon on 7 of the 10 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Rocket Pharmaceuticals and Annexon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Annexon00503.00

Rocket Pharmaceuticals currently has a consensus target price of $59.1818, suggesting a potential upside of 36.52%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Rocket Pharmaceuticals.

Profitability

This table compares Rocket Pharmaceuticals and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
AnnexonN/A-566.22%-32.99%

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Rocket Pharmaceuticals and Annexon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-27.44
AnnexonN/AN/A$-37,180,000.00N/AN/A

Annexon (NASDAQ:ANNX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Annexon and MorphoSys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annexon00503.00
MorphoSys06402.40

Annexon currently has a consensus price target of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than MorphoSys.

Profitability

This table compares Annexon and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnnexonN/A-566.22%-32.99%
MorphoSys8.76%4.51%2.25%

Institutional & Insider Ownership

91.2% of Annexon shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Annexon and MorphoSys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A$-37,180,000.00N/AN/A
MorphoSys$80.43 million33.11$-115,380,000.00($0.91)-22.24

Annexon has higher earnings, but lower revenue than MorphoSys.

Summary

Annexon beats MorphoSys on 5 of the 9 factors compared between the two stocks.


Annexon Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.60-2.5%$2.82 billion$644.77 million-10.50Upcoming Earnings
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.90-3.4%$2.74 billion$306.98 million-5.57Earnings Announcement
Insmed logo
INSM
Insmed
1.2$25.99-25.4%$2.68 billion$136.47 million-10.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$60.89-3.9%$2.68 billion$421.03 million21.44Analyst Report
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.35-1.0%$2.68 billionN/A-23.82Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.24-6.1%$2.66 billion$80.43 million96.39Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.39-3.8%$2.50 billion$182.24 million-8.17News Coverage
Gap Down
Cryoport logo
CYRX
Cryoport
1.7$54.44-15.8%$2.48 billion$33.94 million-93.86Earnings Announcement
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$61.71-5.3%$2.48 billionN/A0.00
Organogenesis logo
ORGO
Organogenesis
1.0$19.29-9.6%$2.47 billion$260.98 million-321.50Analyst Downgrade
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.62-1.0%$2.42 billionN/A0.00
OPKO Health logo
OPK
OPKO Health
1.9$3.54-7.4%$2.37 billion$901.90 million-19.64
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.83-1.6%$2.34 billion$963.01 million14.54Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$37.47-3.1%$2.33 billion$2.11 million-8.11Earnings Announcement
Analyst Revision
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.8$19.97-5.7%$2.33 billion$306.49 million22.44Earnings Announcement
Xencor logo
XNCR
Xencor
1.6$38.14-3.9%$2.22 billion$156.70 million-27.24Earnings Announcement
Analyst Report
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$131.87-1.1%$2.17 billionN/A-11.91Earnings Announcement
Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$126.66-3.1%$2.11 billion$120.28 million-127.94Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.66-2.0%$2.10 billionN/A-27.94Earnings Announcement
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$28.86-5.5%$2.05 billion$15 million-15.11Earnings Announcement
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$26.61-0.6%$2.05 billion$103.54 million-20.01Earnings Announcement
Analyst Downgrade
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$54.39-4.7%$2.04 billionN/A-20.22Gap Down
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$25.90-0.5%$1.98 billion$23.90 million-16.09Earnings Announcement
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.43-3.8%$1.96 billion$410,000.00-5.96News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.8$32.91-4.3%$1.91 billion$25 million-6.58Earnings Announcement
Analyst Revision
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.04-3.4%$1.84 billion$34.51 million-17.13Earnings Announcement
MacroGenics logo
MGNX
MacroGenics
1.4$30.47-4.4%$1.83 billion$64.19 million-9.73
Amarin logo
AMRN
Amarin
1.6$4.59-0.0%$1.81 billion$429.76 million-91.78
FibroGen logo
FGEN
FibroGen
1.8$19.42-4.2%$1.79 billion$256.58 million-7.44
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.99-0.2%$1.77 billion$428.41 million15.93Earnings Announcement
Morphic logo
MORF
Morphic
1.5$47.93-1.6%$1.74 billion$16.98 million-30.72Analyst Report
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$30.16-7.3%$1.71 billionN/A0.00
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.38-3.6%$1.67 billion$26.87 million-12.24Earnings Announcement
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.34-3.4%$1.67 billionN/A-6.53
Kura Oncology logo
KURA
Kura Oncology
1.6$24.74-5.7%$1.64 billionN/A-15.18Earnings Announcement
Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$32.55-4.9%$1.63 billionN/A-3.53Gap Up
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.63-8.6%$1.62 billionN/A0.00Upcoming Earnings
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.56-5.3%$1.61 billion$145.97 million-7.11Earnings Announcement
Upcoming Earnings
High Trading Volume
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.31-2.1%$1.59 billion$1.63 billion12.95Earnings Announcement
Analyst Upgrade
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$34.83-0.5%$1.56 billionN/A0.00Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.35-0.1%$1.56 billion$392.76 million12.18Earnings Announcement
Analyst Revision
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.48-4.9%$1.55 billion$2.34 million-9.53Earnings Announcement
Analyst Report
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$38.62-7.3%$1.55 billionN/A-160.92
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$43.49-5.4%$1.53 billionN/A0.00
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$26.80-3.4%$1.52 billionN/A0.00
uniQure logo
QURE
uniQure
1.7$32.25-0.9%$1.48 billion$7.28 million-8.55Earnings Announcement
Upcoming Earnings
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$40.70-2.2%$1.44 billionN/A0.00Insider Selling
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.45-1.2%$1.41 billion$6.20 million-14.23Upcoming Earnings
Kronos Bio logo
KRON
Kronos Bio
1.7$25.06-2.5%$1.41 billionN/A0.00
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.